These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 1988827)

  • 1. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
    Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
    Derkx B; Wittes J; McCloskey R
    Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
    Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
    Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
    Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
    N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
    Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
    JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
    Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
    Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

  • 19. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
    Bogard WC; Siegel SA; Leone AO; Damiano E; Shealy DJ; Ely TM; Frederick B; Mascelli MA; Siegel RC; Machielse B
    J Immunol; 1993 May; 150(10):4438-49. PubMed ID: 7683319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.